Search
amyloid-beta peptide 40/42 in CSF (Lumipulse G)
Notes:
- used to identify older individuals with preclinical Alzheimer's disease [1]
- FDA-approved May 2022 [2]
Related
A4 amyloid peptide; beta-peptide
cerebrospinal fluid
General
analyte ratio
References
- George J
Driving Patterns Pinpoint Early Alzheimer's Disease.
Subtle shifts in on-road behavior suggest GPS-based biomarkers may have merit.
MedPage Today July 30, 2021
https://www.medpagetoday.com/meetingcoverage/aaic/93840
- George J
Early Alzheimer's Test Gets FDA Nod
First in vitro diagnostic to detect amyloid in early disease setting
MedPage Today May 5, 2022
https://www.medpagetoday.com/neurology/alzheimersdisease/98558
- FDA News Release. May 4, 2022
FDA Permits Marketing for New Test to Improve Diagnosis of Alzheimer's
Disease.
https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-new-test-improve-diagnosis-alzheimers-disease
Components
amyloid-beta peptide 40 in CSF
amyloid-beta peptide 42 in CSF